Company Name : AiRat (Miyagi)
Web Page : https://en.legalontech.jp/
Stage : Series A
Total Raise Amount : ¥579 Million
AiRato Inc., a Miyagi-based startup developing proprietary AI-powered radiation therapy planning software, announces the completion of a ¥460 million (approx. USD 3.3 million) first close of its Pre-Series A funding round.
This round includes follow-on investments from existing backers Chiiki to Hito to Mirai Co., Ltd. , GxPartners LLP, and Mint, along with new participation from Nissay Capital Co., Ltd., Sumitomo Corporation, and 77 Capital Co., Ltd. With this first close, AiRato’s total funding to date has reached ¥580 million (approx. USD 4.2 million).
AiRato’s Vision for the Future
AiRato aims to revolutionize cancer treatment by maximizing the potential of radiation therapy through AI. The company envisions a future where advanced, minimally invasive, and completely pain-free radiation treatments are widely accessible, saving the lives of cancer patients worldwide.
Challenges in Radiation Therapy and AiRato’s Approach
Radiation therapy, one of the three pillars of cancer treatment, has become increasingly vital in aging societies due to its low physical burden on patients. Among cutting-edge techniques, Intensity-Modulated Radiation Therapy (IMRT) has gained significant traction in recent years for its effectiveness.
However, IMRT faces two major challenges:
- Variability in treatment outcomes due to differences in clinician experience
- A shortage of qualified medical professionals, leading to excessive workloads
These challenges have limited the widespread adoption of IMRT, leaving many patients without access to its benefits.
To address this, AiRato is developing and commercializing AI-driven radiation therapy planning software. The software leverages AI to automate critical processes such as tumor and organ contouring, determination of irradiation areas, and safety verification—cutting the time required for treatment planning from six hours to just 10–20 minutes.
This innovation enables the delivery of high-quality, safe radiation therapy plans, unlocking IMRT’s full potential and positioning AiRato as a global leader in radiation oncology technology.
[source]
